Komori
General Meetings of Shareholders4889Renascience Inc.Pharmaceuticals

Notice of Convocation of the 2026 Annual General Meeting of Shareholders and Meeting Materials

The company is proposing to shareholders the holding of the 27th Annual General Meeting of Shareholders, amendments to the Articles of Incorporation, the election of directors and a substitute director who is an Audit and Supervisory Committee Member, a reduction in the capital reserve, and the disposal of surplus.

Worth reading
56In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
1136328774
¥
Wording
Definitive
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Annual (27th)
2026
Jun 25
Date and time(Thursday)23 days from this disclosure to the meeting
Matters for resolution5 items
  1. Partial Amendment to the Articles of Incorporation

  2. Election of 2 directors (excluding directors who are Audit and Supervisory Committee Members)

  3. Election of 1 director who is an Audit and Supervisory Committee Member

  4. Election of 1 alternate Director who is an Audit & Supervisory Committee Member

  5. Reduction in the Amount of Capital Reserve and Disposal of Surplus

Shareholder Proposal

No

A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.
Director nominee
4Nominees
0New
3Outside
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingAnnual (27th)
Date and time10:00 a.m., 25 June 2026 (Thursday)
Matters for resolutionProposal No. 1: Partial Amendment to the Articles of Incorporation, Proposal No. 2: Election of 2 directors (excluding directors who are Audit and Supervisory Committee Members), Proposal No. 3: Election of 1 director who is an Audit and Supervisory Committee Member, Proposal 4: Election of 1 alternate Director who is an Audit & Supervisory Committee Member, Agenda Item No. 5: Reduction in the Amount of Capital Reserve and Disposal of Surplus
Shareholder ProposalNo
Director nominee4 candidates (0 new, 3 outside)
Items this document does not state (1)
Percentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To add medical businesses in the anti-aging and longevity fields and other activities to the company's future business purposes. In addition, to reduce the capital reserve to cover the deficit in retained earnings brought forward and strengthen the company's financial position.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Convocation of the 2026 Annual General Meeting of Shareholders and Meeting Materials | Renascience Inc. (4889) timely disclosure | Komori